earnings
confidence high
sentiment neutral
materiality 0.65
Unicycive Q2 net loss $6.4M; requests FDA Type A meeting for CRL on OLC
Unicycive Therapeutics, Inc.
2025-Q2 EPS
reported -$0.49
vs consensus -$0.75
▲ beat
(+35.1%)
- Net loss of $6.4M vs net income of $3.0M in Q2 2024; R&D expenses down to $1.8M.
- Cash and equivalents $22.3M as of June 30, 2025; runway expected into H2 2026.
- Type A meeting requested with FDA to resolve CRL for oxylanthanum carbonate (OLC).
- Pivotal OLC data published in CJASN: >90% patients achieved phosphate control with low pill burden.
item 2.02item 9.01